Terms: = Liver cancer AND PTPN13, PTP1E, 5783, ENSG00000163629, PTPLE, PTPL1, PNP1, PTP-BAS, DKFZp686J1497, Q12923, FAP-1, PTP-BL
16 results:
1. Network meta-analysis of adjuvant treatments for patients with hepatocellular carcinoma after curative resection.
Ye Y; Wang Y; Xu H; Yi F
BMC Gastroenterol; 2023 Sep; 23(1):320. PubMed ID: 37730533
[TBL] [Abstract] [Full Text] [Related]
2. Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice.
Klose JM; Wosniack J; Iking J; Staniszewska M; Zarrad F; Trajkovic-Arsic M; Herrmann K; Costa PF; Lueckerath K; Fendler WP
J Nucl Med; 2022 Sep; 63(9):1357-1363. PubMed ID: 34992151
[TBL] [Abstract] [Full Text] [Related]
3. Long-term exposure to p-Nitrophenol induces hepatotoxicity via accelerating apoptosis and glycogen accumulation in male Japanese quails.
Ahmed EA; Khaled HE; Elsayed AK
Environ Sci Pollut Res Int; 2021 Aug; 28(32):44420-44431. PubMed ID: 33846926
[TBL] [Abstract] [Full Text] [Related]
4. Anti-oncogene ptpn13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression.
Yan Y; Huang P; Mao K; He C; Xu Q; Zhang M; Liu H; Zhou Z; Zhou Q; Zhou Q; Ou B; Liu Q; Lin J; Chen R; Wang J; Zhang J; Xiao Z
Oncogene; 2021 Jan; 40(1):28-45. PubMed ID: 33051595
[TBL] [Abstract] [Full Text] [Related]
5. Divergent viral presentation among human tumors and adjacent normal tissues.
Cao S; Wendl MC; Wyczalkowski MA; Wylie K; Ye K; Jayasinghe R; Xie M; Wu S; Niu B; Grubb R; Johnson KJ; Gay H; Chen K; Rader JS; Dipersio JF; Chen F; Ding L
Sci Rep; 2016 Jun; 6():28294. PubMed ID: 27339696
[TBL] [Abstract] [Full Text] [Related]
6. Expression of B7-H4 and hepatitis B virus X in hepatitis B virus-related hepatocellular carcinoma.
Hong B; Qian Y; Zhang H; Sang YW; Cheng LF; Wang Q; Gao S; Zheng M; Yao HP
World J Gastroenterol; 2016 May; 22(18):4538-46. PubMed ID: 27182163
[TBL] [Abstract] [Full Text] [Related]
7. Tumour-suppressive role of ptpn13 in hepatocellular carcinoma and its clinical significance.
Zhan H; Jiang J; Luo C; Sun Q; Ke A; Sun C; Hu J; Hu Z; Hu B; Zhu K; Fan J; Zhou J; Huang X
Tumour Biol; 2016 Jul; 37(7):9691-8. PubMed ID: 26801674
[TBL] [Abstract] [Full Text] [Related]
8. An Aza-Cope Reactivity-Based Fluorescent Probe for Imaging Formaldehyde in Living Cells.
Brewer TF; Chang CJ
J Am Chem Soc; 2015 Sep; 137(34):10886-9. PubMed ID: 26306005
[TBL] [Abstract] [Full Text] [Related]
9. Protein tyrosine phosphatases as potential therapeutic targets.
He RJ; Yu ZH; Zhang RY; Zhang ZY
Acta Pharmacol Sin; 2014 Oct; 35(10):1227-46. PubMed ID: 25220640
[TBL] [Abstract] [Full Text] [Related]
10. An expression signature of phenotypic resistance to hepatocellular carcinoma identified by cross-species gene expression analysis.
Frau M; Simile MM; Tomasi ML; Demartis MI; Daino L; Seddaiu MA; Brozzetti S; Feo CF; Massarelli G; Solinas G; Feo F; Lee JS; Pascale RM
Cell Oncol (Dordr); 2012 Jun; 35(3):163-73. PubMed ID: 22434528
[TBL] [Abstract] [Full Text] [Related]
11. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.
Boige V; Raoul JL; Pignon JP; Bouché O; Blanc JF; Dahan L; Jouve JL; Dupouy N; Ducreux M;
Br J Cancer; 2007 Oct; 97(7):862-7. PubMed ID: 17876335
[TBL] [Abstract] [Full Text] [Related]
12. Functional characterization of the promoter of human carbonyl reductase 1 (CBR1). Role of XRE elements in mediating the induction of CBR1 by ligands of the aryl hydrocarbon receptor.
Lakhman SS; Chen X; Gonzalez-Covarrubias V; Schuetz EG; Blanco JG
Mol Pharmacol; 2007 Sep; 72(3):734-43. PubMed ID: 17569794
[TBL] [Abstract] [Full Text] [Related]
13. Genetic characterization of fas-associated phosphatase-1 as a putative tumor suppressor gene on chromosome 4q21.3 in hepatocellular carcinoma.
Yeh SH; Wu DC; Tsai CY; Kuo TJ; Yu WC; Chang YS; Chen CL; Chang CF; Chen DS; Chen PJ
Clin Cancer Res; 2006 Feb; 12(4):1097-108. PubMed ID: 16489062
[TBL] [Abstract] [Full Text] [Related]
14. Expression of Fas and Fas-related molecules in human hepatocellular carcinoma.
Lee SH; Shin MS; Lee HS; Bae JH; Lee HK; Kim HS; Kim SY; Jang JJ; Joo M; Kang YK; Park WS; Park JY; Oh RR; Han SY; Lee JH; Kim SH; Lee JY; Yoo NJ
Hum Pathol; 2001 Mar; 32(3):250-6. PubMed ID: 11274632
[TBL] [Abstract] [Full Text] [Related]
15. In vivo expression of soluble Fas and fap-1: possible mechanisms of Fas resistance in human hepatoblastomas.
Lee SH; Shin MS; Lee JY; Park WS; Kim SY; Jang JJ; Dong SM; Na EY; Kim CS; Kim SH; Yoo NJ
J Pathol; 1999 Jun; 188(2):207-12. PubMed ID: 10398166
[TBL] [Abstract] [Full Text] [Related]
16. Clinical evaluation of hepatic scintigraphy.
Dyrbye M
Acta Med Scand Suppl; 1979; 624():88-92. PubMed ID: 284718
[TBL] [Abstract] [Full Text] [Related]
